These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30123261)

  • 1. Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome.
    Díaz M; Gallego-Escuredo JM; López-Bermejo A; de Zegher F; Villarroya F; Ibáñez L
    Int J Endocrinol; 2018; 2018():4192940. PubMed ID: 30123261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
    García-Beltran C; Cereijo R; Quesada-López T; Malpique R; López-Bermejo A; de Zegher F; Ibáñez L; Villarroya F
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32107266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating follistatin concentrations in adolescent PCOS: Divergent effects of randomized treatments.
    Díaz M; de Zegher F; Ibáñez L
    Front Endocrinol (Lausanne); 2023; 14():1125569. PubMed ID: 36843579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organokines and liver enzymes in adolescent girls with polycystic ovary syndrome during randomized treatments.
    Garcia-Beltran C; Peyrou M; Navarro-Gascon A; López-Bermejo A; de Zegher F; Villarroya F; Ibáñez L
    Front Endocrinol (Lausanne); 2024; 15():1325230. PubMed ID: 38818508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPIOMET4HEALTH-efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial.
    Garcia-Beltran C; Malpique R; Andersen MS; Bas F; Bassols J; Darendeliler F; Díaz M; Dieris B; Fanelli F; Fröhlich-Reiterer E; Gambineri A; Glintborg D; López-Bermejo A; Mann C; Marin S; Obermayer-Pietsch B; Ødegård R; Ravn P; Reinehr T; Renzulli M; Salvador C; Singer V; Vanky E; Torres JV; Yildiz M; de Zegher F; Ibáñez L
    Trials; 2023 Sep; 24(1):589. PubMed ID: 37715279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat.
    de Zegher F; Díaz M; Villarroya J; Cairó M; López-Bermejo A; Villarroya F; Ibáñez L
    Sci Rep; 2021 Mar; 11(1):7018. PubMed ID: 33782413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Circulating Levels of miR-451a in Girls with Polycystic Ovary Syndrome: Different Effects of Randomized Treatments.
    Díaz M; Bassols J; López-Bermejo A; de Zegher F; Ibáñez L
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31730174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
    Ibáñez L; Del Río L; Díaz M; Sebastiani G; Pozo ÓJ; López-Bermejo A; de Zegher F
    J Adolesc Health; 2017 Oct; 61(4):446-453. PubMed ID: 28712591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a circulating marker of hepato-visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome - Evidence from randomized clinical trials.
    Malpique R; Sánchez-Infantes D; Garcia-Beltran C; Taxerås SD; López-Bermejo A; de Zegher F; Ibáñez L
    Pediatr Obes; 2019 May; 14(5):e12500. PubMed ID: 30653851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota in adolescent girls with polycystic ovary syndrome: Effects of randomized treatments.
    Garcia-Beltran C; Malpique R; Carbonetto B; González-Torres P; Henares D; Brotons P; Muñoz-Almagro C; López-Bermejo A; de Zegher F; Ibáñez L
    Pediatr Obes; 2021 Apr; 16(4):e12734. PubMed ID: 32989872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adolescent polycystic ovary syndrome without obesity: HOTAIR rs1443512 genotype relates to fat mass and to the redistribution of fat mass on low-dose pioglitazone.
    de Zegher F; Díaz M; Ibáñez L
    J Endocrinol Invest; 2024 Apr; 47(4):1037-1043. PubMed ID: 37805962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raised Thyroid-Stimulating Hormone in Girls with Polycystic Ovary Syndrome: Effects of Randomized Interventions.
    Garcia-Beltran C; Bassols J; Carreras-Badosa G; López Bermejo A; Ibáñez L; de Zegher F
    Horm Res Paediatr; 2023; 96(5):458-464. PubMed ID: 36649684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward a Treatment Normalizing Ovulation Rate in Adolescent Girls With Polycystic Ovary Syndrome.
    Ibáñez L; Díaz M; García-Beltrán C; Malpique R; Garde E; López-Bermejo A; de Zegher F
    J Endocr Soc; 2020 May; 4(5):bvaa032. PubMed ID: 32342022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic ovary syndrome in adolescent girls.
    Ibáñez L; de Zegher F
    Pediatr Obes; 2020 Feb; 15(2):e12586. PubMed ID: 31663293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
    Ibáñez L; de Zegher F
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of half-dose spiomet treatment in girls with early puberty and accelerated bone maturation: a multicenter, randomized, placebo-controlled study protocol.
    Bassols J; de Zegher F; Diaz M; Carreras-Badosa G; Garcia-Beltran C; Puerto-Carranza E; Oliver-Vila C; Casano P; Franco CA; Malpique R; López-Bermejo A; Ibáñez L
    Trials; 2023 Jan; 24(1):56. PubMed ID: 36694227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic Changes in Circulating Endocrine FGF19 Subfamily and Fetuin-A in Response to Intralipid and Insulin Infusions in Healthy and PCOS Women.
    Ramanjaneya M; Bensila M; Bettahi I; Jerobin J; Samra TA; Aye MM; Alkasem M; Siveen KS; Sathyapalan T; Skarulis M; Atkin SL; Abou-Samra AB
    Front Endocrinol (Lausanne); 2020; 11():568500. PubMed ID: 33101202
    [No Abstract]   [Full Text] [Related]  

  • 19. Investigating Fetuin-A and Paraoxonase-1 Activity as Markers in Polycystic Ovary Syndrome Based on Body Mass Index: A Prospective Case-Control Study.
    Gurbuz T; Alanya Tosun S; Cebi A; Gokmen O; Usta M
    Cureus; 2021 Oct; 13(10):e18553. PubMed ID: 34754696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment.
    Ibáñez L; Valls C; Marcos MV; Ong K; Dunger DB; De Zegher F
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4331-7. PubMed ID: 15356029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.